Taxane

Where the papers sit

22 papers from the last 6 months study taxane directly · updated from PubMed 7 Oct 2026

• Taxane Treatment Optimization

  Taxane treatment optimization centers on targeted delivery, drug combinations, resistance reversal, and toxicity prediction. Breast cancer studies pair paclitaxel with quercetin, photothermal therapy, carboplatin, or BRCA-directed treatment strategies. Nanovesicles, micelles, solid dispersions, and ultrasound-responsive systems aim to improve tumor exposure, while ABCB1 targeting addresses docetaxel resistance. Peripheral neuropathy remains a clinical constraint, with nailfold capillaroscopy explored for risk prediction.

  12 papers · 54.5%

• Taxane Therapy in Head and Neck Cancer

  Taxane-based combination therapy is being tested before surgery and alongside radiation for locally advanced head and neck cancers. Paclitaxel, carboplatin, and cetuximab are used to seek better clinical and pathological responses, while liposomal doxorubicin plus nab-paclitaxel is studied in adenoid cystic carcinoma. Patient-derived tongue cancer models extend response testing beyond standard clinical cohorts. Reduced dexamethasone premedication reflects a parallel effort to limit steroid exposure without increasing paclitaxel hypersensitivity.

  4 papers · 18.2%

• Second-Line Therapy in NSCLC

  Second-line NSCLC treatment is shifting toward post-immunotherapy comparisons between docetaxel-based therapy and molecularly targeted options. Docetaxel plus ramucirumab is being evaluated immediately after immunotherapy, with emphasis on efficacy, durability, and safety. Real-world analyses compare this chemotherapy standard with sotorasib in advanced or metastatic disease. The open question is whether KRAS-directed treatment provides more durable benefit than docetaxel monotherapy outside trial-selected populations.

  2 papers · 9.1%

• Others — Cross-Cancer Chemotherapy Studies

  Taxane chemotherapy appears across advanced gastric, pancreatic, and bladder cancer studies, but the clinical questions differ. Ramucirumab-taxane therapy after nivolumab focuses on outcomes in advanced gastric cancer. Nab-paclitaxel plus S-1 is being evaluated for locally advanced pancreatic cancer, while bladder cancer work uses MRI radiomics to classify response and immune states. No single disease or treatment question unifies the cluster.

  4 papers · 18.2%